My weekly thoughts on $TMDX ... this is one of the most mispriced / undervalued stocks in the market IF the company is able to hit/surpass management targets which are: ~10k OCS cases by 2028 ~20k OCS cases by 2030 ~30k OCS cases by 2032 ***these case targets are just OCS and don't include CHOPS which I think could add another 10-15% to the totals in 2030 and 2032. Last year $TMDX did 5,139 OCS cases... let's assume this year that number increases by 24% to 6,372 If I'm right that CHOPS adds 10-15% to the totals, then $TMDX should do 34,500+ cases in 2032. If $TMDX does 6,372 cases in 2026, it implies that cases need to grow at a 32.5% CAGR for the next 6 years. I think ASP drops by an average of ~5% per year as they introduce CHOPS and OCS Kidney while expanding to Europe... which me
View on X ↗